VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 15,600 Shares of Halozyme Therapeutics, Inc. $HALO

VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 119.1% in the third quarter, Holdings Channel.com reports. The fund owned 28,700 shares of the biopharmaceutical company’s stock after acquiring an additional 15,600 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Halozyme Therapeutics were worth $3,168,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mather Group LLC. boosted its stake in shares of Halozyme Therapeutics by 48.9% in the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 136 shares during the last quarter. North Dakota State Investment Board increased its position in shares of Halozyme Therapeutics by 4.3% during the third quarter. North Dakota State Investment Board now owns 3,598 shares of the biopharmaceutical company’s stock worth $397,000 after purchasing an additional 147 shares in the last quarter. CoreCap Advisors LLC raised its stake in Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its stake in Halozyme Therapeutics by 3.5% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,515 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 151 shares during the last quarter. Finally, Twin Capital Management Inc. lifted its holdings in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $128.95 on Tuesday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The stock has a market cap of $14.64 billion, a PE ratio of 38.49, a P/E/G ratio of 0.49 and a beta of 0.88. The stock has a 50 day moving average price of $114.12 and a 200 day moving average price of $83.74.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. TD Cowen increased their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Finally, Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.55.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 in the last three months. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.